155 related articles for article (PubMed ID: 7947080)
1. Detection of the anti-p53 antibody response in malignant and benign pancreatic disease.
Marxsen J; Schmiegel W; Röder C; Harder R; Juhl H; Henne-Bruns D; Kremer B; Kalthoff H
Br J Cancer; 1994 Nov; 70(5):1031-4. PubMed ID: 7947080
[TBL] [Abstract][Full Text] [Related]
2. The role of anti-p53-autoantibodies in pancreatic disorders.
Gansauge S; Gansauge F; Negri G; Galle P; Müller J; Nüssler AK; Poch B; Beger HG
Int J Pancreatol; 1996 Jun; 19(3):171-8. PubMed ID: 8807362
[TBL] [Abstract][Full Text] [Related]
3. p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma.
Raedle J; Oremek G; Welker M; Roth WK; Caspary WF; Zeuzem S
Pancreas; 1996 Oct; 13(3):241-6. PubMed ID: 8884844
[TBL] [Abstract][Full Text] [Related]
4. Implications of p53 alterations and anti-p53 antibody response in head and neck squamous cell carcinomas.
Lavieille JP; Righini C; Reyt E; Brambilla C; Riva C
Oral Oncol; 1998 Mar; 34(2):84-92. PubMed ID: 9682769
[TBL] [Abstract][Full Text] [Related]
5. Clinical implication of anti-p53 antibodies and p53-protein in pancreatic disease.
Ohshio G; Suwa H; Imamura M
Int J Gastrointest Cancer; 2002; 31(1-3):129-35. PubMed ID: 12622424
[TBL] [Abstract][Full Text] [Related]
6. [Detection of serum anti-p53 antibodies in patients with various types of cancer].
Sakai H
Rinsho Byori; 2002 Jan; 50(1):90-2. PubMed ID: 11871143
[TBL] [Abstract][Full Text] [Related]
7. Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases.
Laurent-Puig P; Lubin R; Semhoun-Ducloux S; Pelletier G; Fourre C; Ducreux M; Briantais MJ; Buffet C; Soussi T
Gut; 1995 Mar; 36(3):455-8. PubMed ID: 7698709
[TBL] [Abstract][Full Text] [Related]
8. Anti-p53 and anti-heat shock proteins antibodies in patients with malignant or pre-malignant lesions of the oral cavity.
Castelli M; Cianfriglia F; Manieri A; Palma L; Pezzuto RW; Falasca G; Delpino A
Anticancer Res; 2001; 21(1B):753-8. PubMed ID: 11299839
[TBL] [Abstract][Full Text] [Related]
9. The presence of anti-p53 antibodies in sera from patients with oesophageal carcinoma: correlation to treatment, tumour volume and survival.
Bergström S; Dreilich M; Wagenius G; Brattström D; Larsson A; Hesselius P; Bergqvist M
In Vivo; 2004; 18(5):615-20. PubMed ID: 15523902
[TBL] [Abstract][Full Text] [Related]
10. Measurement and evaluation of serum anti-p53 antibody levels in patients with lung cancer at its initial presentation: a prospective study.
Segawa Y; Kageyama M; Suzuki S; Jinno K; Takigawa N; Fujimoto N; Hotta K; Eguchi K
Br J Cancer; 1998 Sep; 78(5):667-72. PubMed ID: 9744508
[TBL] [Abstract][Full Text] [Related]
11. Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma.
Ryder SD; Rizzi PM; Volkmann M; Metivier E; Pereira LM; Galle PR; Naoumov NV; Zentgraf H; Williams R
J Clin Pathol; 1996 Apr; 49(4):295-9. PubMed ID: 8655704
[TBL] [Abstract][Full Text] [Related]
12. p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.
Creaney J; McLaren BM; Stevenson S; Musk AW; de Klerk N; Robinson BW; Lake RA
Br J Cancer; 2001 Jan; 84(1):52-6. PubMed ID: 11139313
[TBL] [Abstract][Full Text] [Related]
13. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
Qiu LL; Hua PY; Ye LL; Wang YC; Qiu T; Bao HZ; Wang L
Cancer Detect Prev; 2007; 31(1):45-9. PubMed ID: 17292563
[TBL] [Abstract][Full Text] [Related]
14. Serum p53 antibodies as early markers of lung cancer.
Lubin R; Zalcman G; Bouchet L; Trédanel J; Legros Y; Cazals D; Hirsch A; Soussi T
Nat Med; 1995 Jul; 1(7):701-2. PubMed ID: 7585154
[TBL] [Abstract][Full Text] [Related]
15. Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer.
Hammel P; Leroy-Viard K; Chaumette MT; Villaudy J; Falzone MC; Rouillard D; Hamelin R; Boissier B; Remvikos Y
Int J Cancer; 1999 May; 81(5):712-8. PubMed ID: 10328221
[TBL] [Abstract][Full Text] [Related]
16. Detection of serum anti-P53 antibodies from patients with colorectal cancer in China using a combination of P53- and phage-ELISA: correlation to clinical parameters.
Wu J; Qiu T; Pan P; Yu D; Ju Z; Qu X; Gao X; Mao C; Wang L
Asian Pac J Cancer Prev; 2011; 12(11):2921-4. PubMed ID: 22393964
[TBL] [Abstract][Full Text] [Related]
17. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP
Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237
[TBL] [Abstract][Full Text] [Related]
18. Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck.
Lavieille JP; Lubin R; Soussi T; Reyt E; Brambilla C; Riva C
Anticancer Res; 1996; 16(4C):2385-8. PubMed ID: 8816839
[TBL] [Abstract][Full Text] [Related]
19. Detection of anti-p53 antibodies by ELISA using p53 synthetic or phage-displayed peptides.
Portefaix JM; Fanutti C; Granier C; Crapez E; Perham R; Grenier J; Pau B; Del Rio M
J Immunol Methods; 2002 Jan; 259(1-2):65-75. PubMed ID: 11730842
[TBL] [Abstract][Full Text] [Related]
20. Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies.
Moch C; Moysan A; Lubin R; de la Salmonière P; Soufir N; Galisson F; Vilmer C; Venutolo E; Le Pelletier F; Janin A; Basset-Séguin N
Br J Cancer; 2001 Dec; 85(12):1883-6. PubMed ID: 11747330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
